Pridopidine hydrochloride is under clinical development by Prilenia Therapeutics Development and currently in Phase III for Huntington Disease.

David Wayne Magnusson David Wayne Magnusson, 72, passed away peacefully on Dec. 13, 2024 due to complications of Parkinson’s disease. He was diagnosed ...

Alterity Therapeutics Limited (NASDAQ:ATHE – Get Free Report) was the target of a large increase in short interest in December. As of December 15th, there was short interest totalling 148,600 shares, ...

Acetylcysteine zidrimer is under clinical development by Orpheris and currently in Phase I for Parkinson's Disease.

Denny is the cutie that has taken Virgin River by storm. But with his Huntington’s diagnosis comes some seriously scary health news.

PADOVA study showed numerical delay in motor progression and positive trends on multiple secondary and exploratory endpoints; ...

Stock analysts at Maxim Group started coverage on shares of Alterity Therapeutics (NASDAQ:ATHE – Get Free Report) in a research report issued on Thursday, MarketBeat.com reports. The brokerage set a ...

However, abnormal behavior in these proteins can lead to neurodegenerative disorders, including Parkinson's disease, dementia and Huntington's disease. La Trobe University researcher Dr. Shouxiang ...

A new gene editing tool that helps cellular machinery skip parts of genes responsible for diseases has been applied to reduce the formation of amyloid-beta plaque precursors in a mouse model of ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the Phase IIb PADOVA study investigating prasinezumab in 586 people with early-stage Parkinson’s ...